Solvonis Therapeutics plc Announces US Patent Office Allows Ketamine Patent Across All Behavioural Addictions

Solvonis secures broad US patent allowance for ketamine in behavioural addictions, targeting large unmet markets.

What the company is saying

Solvonis Therapeutics plc announces that the US Patent and Trademark Office has allowed its method-of-use patent application for treating all behavioural addictions with ketamine at dissociative doses of at least 50 mg. The company frames this as a major milestone, highlighting the breadth of the allowed claims, which cover conditions including binge eating, gambling, gaming, and compulsive sexual behaviour disorders, using racemic ketamine, esketamine, or arketamine, by any route, with or without psychotherapy. The announcement emphasizes the scale of the opportunity, citing over 48 million Americans affected by behavioural addictions, with binge eating and gambling as initial commercial priorities. Executives Professor David Nutt (Chief Scientific Officer) and Anthony Tennyson (Chief Executive Officer) stress the potential for multiple partnerships and licensing deals, and the expansion of Solvonis’ commercial opportunity alongside its Phase 3 alcohol programme and NIDA-funded work on cocaine and methamphetamine addiction. The company references a sector precedent—Otsuka’s June 2026 acquisition of Transcend for US$700 million upfront plus up to US$525 million in sales-related payments—to illustrate the commercial value of method-of-use patents. The tone is confident and forward-looking, positioning Solvonis as building a substantial behavioural-addiction business and pursuing non-dilutive funding and partners.

What the data suggests

The patent allowance covers all behavioural addictions treated with ketamine at dissociative doses of at least 50 mg, with the grant expected in Q1 2027 and a projected patent term to May 2042. The claims include use of racemic ketamine, esketamine, and arketamine, by any route, with or without psychotherapy, and span binge eating, gambling, gaming, and compulsive sexual behaviour disorders. Prevalence data cited includes over 48 million Americans affected by behavioural addictions, 1.2% of adults affected annually by binge eating disorder (2.8% lifetime), and approximately 9 million Americans experiencing problem gambling, including 2.5 million with severe problems. There is only one FDA-approved medicine for moderate-to-severe binge eating disorder (lisdexamfetamine) and none for gambling disorder, indicating significant unmet need. The announcement references Otsuka’s acquisition of Transcend for US$700 million upfront plus up to US$525 million in sales-related payments as a commercial precedent for method-of-use patents, but provides no direct financials or revenue figures for Solvonis. Solvonis’ pipeline includes SVN-001 (Phase 3, severe alcohol use disorder), SVN-002 (Phase 2b planning, moderate-to-severe AUD), SVN-015 (preclinical, cocaine and methamphetamine addiction), and SVN-114 (preclinical, PTSD). All programmes are investigational and lack regulatory approval. The data supports a broad intellectual property position and large target markets, but commercialisation and revenue remain unproven.

Analysis

The announcement is upbeat, highlighting the allowance of a broad US patent for ketamine-based treatments of behavioural addictions, which is a meaningful intellectual property milestone. However, the majority of the claims are forward-looking: the patent is not yet granted (expected Q1 2027), all clinical programmes are investigational with no regulatory approvals, and commercialisation is positioned as a future opportunity. The release references large market sizes and a high-value sector precedent (Otsuka/Transcend), but provides no financials, revenue, or profitability data for Solvonis itself. The narrative inflates the signal by drawing parallels to major industry deals and projecting substantial commercial potential, yet the only realised facts are the patent allowance (not grant) and ongoing clinical/preclinical work. There is no evidence of immediate revenue or near-term earnings impact, and the benefits are long-dated and uncertain. The absence of disclosed capital outlay or imminent spend means the capital intensity flag is not triggered, but the overall tone is more promotional than the current stage justifies.

Risk flags

• ●The patent is not yet granted; it is only an allowance, with grant expected in Q1 2027. Any delay or failure in completing formalities could postpone or prevent the commercial protection Solvonis is seeking.
• ●All clinical programmes are investigational and have not received regulatory approval. There is no guarantee that trials will succeed or that regulatory bodies will approve ketamine-based treatments for behavioural addictions.
• ●The announcement relies heavily on sector precedent (Otsuka’s $700 million upfront acquisition of Transcend) to imply commercial potential, but provides no direct evidence that Solvonis will achieve similar outcomes. The path from patent allowance to commercial success is unproven and contingent on multiple uncertain steps.
• ●No financial data, revenue, or funding runway is disclosed for Solvonis. The ability to fund ongoing and future clinical trials, as well as to execute on partnering or licensing strategies, is not demonstrated in this announcement.
• ●The addressable market figures are large, but actual market access depends on successful clinical development, regulatory approval, and payer acceptance, all of which remain uncertain.

Bottom line

Solvonis has achieved a broad US patent allowance for ketamine-based treatment of behavioural addictions, targeting large and underserved markets such as binge eating and gambling disorders. The company’s claims are supported by substantial prevalence data and a strong intellectual property position, but all clinical programmes remain investigational and unapproved. The reference to Otsuka’s $700 million-plus acquisition of Transcend highlights the potential value of method-of-use patents, but Solvonis has not yet demonstrated comparable clinical or commercial progress. The timeline to value is long, with the patent grant expected in Q1 2027 and clinical milestones still ahead. Investors should focus on the formal patent grant, clinical trial results, and evidence of partnership or licensing deals as the next key catalysts. The most important takeaway is that while the patent allowance is a significant strategic asset, commercial and financial outcomes remain distant and highly contingent on future execution.

Announcement summary

(LSE: SVNS) Solvonis Therapeutics plc, a clinical-stage biotechnology company based in the United Kingdom, announced that the US Patent and Trademark Office (USPTO) has allowed its method-of-use patent application covering the treatment of all behavioural addictions with ketamine at dissociative doses of at least 50 mg. The allowed claims provide Solvonis with a broad US patent position across behavioural addictions, including binge eating, gambling, gaming, and compulsive sexual behaviour disorders, using racemic ketamine, esketamine, or arketamine, by any route, with or without psychotherapy. The patent grant is expected in Q1 2027, subject to final formalities, with an anticipated patent term to May 2042. Over 48 million Americans are estimated to be affected by behavioural addictions, including gambling and food-related compulsive behaviours. US research estimates that 1.2% of adults are affected by binge eating disorder annually and 2.8% during their lifetime, with lisdexamfetamine being the only FDA-approved medicine for moderate-to-severe binge eating disorder in adults. Approximately 9 million Americans experience problem gambling, including around 2.5 million adults with severe problems, and there is currently no FDA-approved medicine for gambling disorder. The patent allowance supports Solvonis' commercial strategy to protect new treatment uses, build clinical evidence, and pursue partnering and out-licensing opportunities. The company’s Phase 3 alcohol trial for SVN-001 is co-funded by Solvonis, the National Institute for Health and Care Research (NIHR), and the Medical Research Council (MRC), while the US National Institute on Drug Abuse (NIDA) funds and conducts further preclinical studies of SVN-015 for cocaine and methamphetamine addiction. Solvonis retains ownership of its compounds and intellectual property. The patent application was originally filed in May 2022 by Awakn Life Sciences, now part of Solvonis. Commercial precedent is cited with Otsuka’s June 2026 acquisition of Transcend for US$700 million upfront plus up to US$525 million in sales-related payments, following a granted US method-of-use patent and positive Phase 2 results. Solvonis’ pipeline includes SVN-001 (ketamine-based, Phase 3 for severe alcohol use disorder in the UK), SVN-002 (esketamine oral thin film, Phase 2b planning for moderate-to-severe AUD in the US, with FDA-agreed 505(b)(2) pathway and formulation patents granted in the US and Europe), SVN-015 (proprietary compound in NIDA-funded preclinical studies for cocaine and methamphetamine addiction and a separate programme for major depressive disorder with anhedonia), and SVN-114 (preclinical novel entactogen for PTSD). All programmes are investigational and have not received regulatory approval. Professor David Nutt, Chief Scientific Officer, and Anthony Tennyson, Chief Executive Officer, commented on the significance of the patent milestone and the company’s strategy to pursue non-dilutive funding and partnerships to build clinical evidence and long-term shareholder value.

Disagree with this article?